BR112015019348A2 - Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária - Google Patents

Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária

Info

Publication number
BR112015019348A2
BR112015019348A2 BR112015019348A BR112015019348A BR112015019348A2 BR 112015019348 A2 BR112015019348 A2 BR 112015019348A2 BR 112015019348 A BR112015019348 A BR 112015019348A BR 112015019348 A BR112015019348 A BR 112015019348A BR 112015019348 A2 BR112015019348 A2 BR 112015019348A2
Authority
BR
Brazil
Prior art keywords
sialyl transferase
sialylation
protein
glycosylation modified
enhanced
Prior art date
Application number
BR112015019348A
Other languages
English (en)
Inventor
M Meade Harry
Chen Li-How
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BR112015019348A2 publication Critical patent/BR112015019348A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MÉTODOS PARA PRODUÇÃO DE PROTEÍNA COM GLICOSILAÇÃO MODIFICADA E COM SIALILAÇÃO AUMENTADA, PARA AUMENTAR A ATIVIDADE DE SIALIL TRANSFERASE NA GLÂNDULA MAMÁRIA E PARA PRODUZIR SIALIL TRANSFERASE, PROTEÍNA COM GLICOSILAÇÃO MODIFICADA OU PROTEÍNA COM SIALILAÇÃO AUMENTADA, COMPOSIÇÃO, E, CÉLULA EPITELIAL MAMÁRIA. Em um aspecto, a descrição provê proteínas com glicosilação modificada e métodos para a sua produção. De acordo com um aspecto, a descrição provê animais e células transgênicos para a produção de proteínas com glicosilação modificada. Em algumas modalidades, a glicosilação modificada é sialilação aumentada.
BR112015019348A 2013-02-13 2014-02-13 Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária BR112015019348A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764502P 2013-02-13 2013-02-13
PCT/IB2014/001236 WO2014140927A2 (en) 2013-02-13 2014-02-13 Proteins with modified glycosylation and methods of production thereof

Publications (1)

Publication Number Publication Date
BR112015019348A2 true BR112015019348A2 (pt) 2017-08-22

Family

ID=51355563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019348A BR112015019348A2 (pt) 2013-02-13 2014-02-13 Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária

Country Status (7)

Country Link
US (1) US10034921B2 (pt)
EP (1) EP2956003A2 (pt)
CN (1) CN105263319A (pt)
AR (1) AR094778A1 (pt)
BR (1) BR112015019348A2 (pt)
TW (1) TW201446962A (pt)
WO (1) WO2014140927A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
US9764009B2 (en) * 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP2956480B1 (en) 2013-02-13 2019-09-04 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
CN105358228A (zh) 2013-07-05 2016-02-24 法国血液分割暨生化制品实验室 亲和层析基质
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
US20180139938A1 (en) * 2015-05-04 2018-05-24 Laboratoire Français du Fractionnement et des, Biotechnologies Transgenic production of fc fusion proteins
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
CN113785071A (zh) * 2019-03-29 2021-12-10 新加坡科技研究局 唾液酸化蛋白质的方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
EP0114589B1 (en) 1982-12-20 1987-09-23 The President And Fellows Of Harvard College Inhibition of angiogenesis
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
GB8615942D0 (en) 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
WO1988001648A1 (en) 1986-08-28 1988-03-10 Immunex Corporation Expression of heterologous proteins by transgenic lactating mammals
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8826446D0 (en) 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ES2090299T3 (es) 1989-12-01 1996-10-16 Pharming Bv Produccion de polipeptidos recombinantes mediante especies bovinas y metodos transgenicos.
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE4000939A1 (de) 1990-01-15 1991-07-18 Brem Gottfried Prof Dr Dr Verfahren zur antikoerpergewinnung
US5416017A (en) 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
EP0512090B2 (en) 1990-10-16 2006-11-22 Sonoran Desert Chemicals LLC Treatment of inflammation
US5648253A (en) 1990-12-20 1997-07-15 Tsi Corporation Inhibitor-resistant urokinase
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
JPH06507307A (ja) 1991-01-11 1994-08-25 アメリカン・レツド・クロス トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
EP0597010A4 (en) 1991-07-31 1996-12-27 Rhone Poulenc Rorer Int Transgenic protein production.
US6448469B1 (en) 1991-10-02 2002-09-10 Genzyme Corporation Production of membrane proteins in the milk of transgenic nonhuman mammals
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
US6204431B1 (en) * 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
JPH09509847A (ja) 1994-03-09 1997-10-07 アボツト・ラボラトリーズ 人乳化乳
MX198456B (es) 1994-03-09 2000-09-05 Abbott Lab Animales trangenicos que producen oligosacaridos y glucoconjugados.
US5780009A (en) 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
EP0871671A1 (en) 1995-09-07 1998-10-21 PPL Therapeutics (Scotland) Limited Purification of alpha-1 proteinase inhibitor
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6271436B1 (en) 1996-10-11 2001-08-07 The Texas A & M University System Cells and methods for the generation of transgenic pigs
US6063905A (en) 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
WO1998037224A1 (en) 1997-02-25 1998-08-27 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
EP0977837A1 (en) 1997-04-03 2000-02-09 Universite Laval Transgenic expression in genital tract and sexual accessory glands
CA2291487A1 (en) 1997-05-29 1998-12-03 New Zealand Pastoral Agriculture Research Institute Limited Processes for production of immunoglobulin a in milk
US6210736B1 (en) 1997-06-17 2001-04-03 Genzyme Transgenics Corporation Transgenically produced prolactin
US20040019923A1 (en) * 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US6593463B1 (en) 1997-10-20 2003-07-15 Genzyme Transgenics Corporation Modified MSP-1 nucleic acid sequences and methods for increasing MRNA levels and protein expression in cell systems
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
EP1088084B1 (en) 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion protein
US20030005468A1 (en) 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
US20040117863A1 (en) 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
EP1818397A1 (en) 1998-11-02 2007-08-15 Trustees Of Tufts College Methods for cloning animals
US20030177513A1 (en) 1998-11-02 2003-09-18 Yann Echelard Transgenic and cloned mammals
US6580017B1 (en) 1998-11-02 2003-06-17 Genzyme Transgenics Corporation Methods of reconstructed goat embryo transfer
WO2000030436A1 (en) 1998-11-19 2000-06-02 Ppl Therapeutics (Scotland) Ltd. Stabilisation of milk from transgenic animals
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
WO2000050057A1 (en) 1999-02-22 2000-08-31 Bernstein Eric F Compositions and methods for prevention of photoaging
WO2001000855A1 (en) 1999-06-23 2001-01-04 Ppl Therapeutics (Scotland) Ltd. Fusion proteins incorporating lysozyme
HUP0203537A2 (hu) 1999-10-14 2003-02-28 Genzyme Transgenics Corporation Célmolekula transzgénikus állatban történő előállítására és tisztítására szolgáló eljárások
US7414170B2 (en) 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20040205832A1 (en) 2000-05-05 2004-10-14 Meade Harry M. Transgenically produced decorin
JP2004500890A (ja) 2000-06-19 2004-01-15 ジーティーシー　バイオセラピューティックス　インコーポレイテッド 遺伝子導入によって作成された血小板由来増殖因子
US6924412B1 (en) 2000-07-21 2005-08-02 Arriwan Holding B.V. Means and methods for raising antibody concentration in compartments of the body of a non-human animal
CA2417595A1 (en) 2000-08-10 2002-02-14 Genzyme Transgenics Corporation Cryopreservation of sperm
DE10045047A1 (de) 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk METHOD FOR PURIFYING ANTIBODIES
US20040226052A1 (en) 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
IL156618A0 (en) 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
US20030036637A1 (en) 2001-06-13 2003-02-20 Scott Fulton Purification of human serum albumin
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2328025T3 (es) 2001-10-09 2009-11-06 Mayo Foundation For Medical Education And Research Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
EP2305314B1 (en) 2001-10-10 2015-12-23 ratiopharm GmbH Remodelling and glycoconjugation of antibodies
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
EP1463802A1 (en) 2002-01-11 2004-10-06 GTC Biotherapeutics, Inc. Method and system for fusion and activation following nuclear transfer in reconstructed embryos
US20040133931A1 (en) 2003-01-08 2004-07-08 Gavin William G. Method and system for fusion and activation following nuclear transfer in reconstructed embryos
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003230725A1 (en) 2002-04-01 2003-10-20 Gtc Biotherapeutics, Inc. A method for selecting cell lines to be used for nuclear transfer in mammalian species
JP2005527570A (ja) 2002-04-01 2005-09-15 ジーティーシー バイオセラピューティックス インコーポレイテッド 肺障害の治療
CA2492561A1 (en) 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
CN1688190A (zh) 2002-08-01 2005-10-26 Gtc生物治疗学公司 用于由体细胞核转移生产转基因动物的纯合原代细胞系的快速筛选方法
WO2004026427A2 (en) 2002-09-17 2004-04-01 Gtc Biotherapeutics, Inc. Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
US20040102380A1 (en) 2002-11-18 2004-05-27 Fulton Scott P. Method for continuous, automated blending of solutions from acids and bases
US7087719B2 (en) 2002-11-19 2006-08-08 Gtc Biotherapeutics, Inc. Method for the crystallization of human serum albumin
US20050097625A1 (en) 2002-11-27 2005-05-05 Meade Harry M. Modified antibodies stably produced in milk and methods of producing same
EP1578192A4 (en) 2002-12-10 2006-03-29 Gtc Biotherapeutics Inc METHOD AND SYSTEM FOR USING SOMATIC CELL CELL NUCLEAR TRANSFER EMBRYOS AS CELL DONORS FOR ADDITIONAL NUCLEAR TRANSFER
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2516836A1 (en) 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US7550263B2 (en) 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
AU2004281642A1 (en) 2003-09-15 2005-04-28 Gtc Biotherapeutics, Inc. Expression of dominant negative transmembrane receptors in the milk of transgenic animals
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050186608A1 (en) 2004-02-19 2005-08-25 Olsen Byron V. Method for the production of transgenic proteins useful in the treatment of obesity and diabetes
US20050192226A1 (en) 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050197496A1 (en) 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
US7667089B2 (en) 2004-04-09 2010-02-23 National Chung Hsing University Transgenic mammal secreting B-domain deleted human FVII in its milk
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20050245444A1 (en) 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
JP2008515772A (ja) 2004-07-21 2008-05-15 グライコフィ， インコーポレイテッド Ｇａｌ２ＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを支配的に含む免疫グロブリン
ES2281222B1 (es) * 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
US20060123500A1 (en) 2004-12-07 2006-06-08 Gtc Biotherapeutics, Inc. Methods of prescreening cells for nuclear transfer procedures
US20060121004A1 (en) 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20060130159A1 (en) 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US20060168671A1 (en) 2005-01-21 2006-07-27 Gavin William G Injection of caprine sperm factor (cSF), phospholipase C zeta (PLCzeta) and adenophostin A as alternative methods of activation during nuclear transfer in the caprine species
US20060182744A1 (en) 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20080019905A9 (en) 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060286548A1 (en) 2005-06-16 2006-12-21 Gregory Liposky Method of making recombinant human antibodies for use in biosensor technology
ES2543685T3 (es) 2005-06-30 2015-08-21 Janssen Biotech, Inc. Métodos y composiciones con actividad terapéutica mejorada
US20070037192A1 (en) 2005-07-25 2007-02-15 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
JP2009507482A (ja) 2005-09-09 2009-02-26 グライコフィ， インコーポレイテッド 主にｍａｎ７ｇｌｃｎａｃ２、ｍａｎ８ｇｌｃｎａｃ２グリコフォームを含むイムノグロブリン
JP5328019B2 (ja) 2005-10-21 2013-10-30 レヴォ バイオロジクス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
US7700321B2 (en) 2005-10-21 2010-04-20 Genzyme Corporation Antibody-based therapeutics with enhanced ADCC activity
CA2641872A1 (en) 2006-02-09 2007-08-16 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN101460522B (zh) 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
WO2007124019A2 (en) 2006-04-21 2007-11-01 Gtc Biotherapeutics, Inc. Methods and products related to the transfer of molecules from blood to the mammary gland
WO2007146847A2 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
ZA200901912B (en) 2006-09-10 2010-06-30 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PT2073842E (pt) 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
CN1944645A (zh) * 2006-10-17 2007-04-11 青岛森淼生物技术研究所 利用乳腺生物反应器制备重组人的抗凝血酶ⅲ蛋白的方法
ES2415604T3 (es) 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
CN101802210A (zh) * 2007-06-13 2010-08-11 斯特林贝尔德生物技术北美公司 在奶中产生外源蛋白的转基因哺乳动物
BRPI0907239A2 (pt) * 2008-01-07 2017-06-13 Synageva Biopharma Corp métodos para isolar uma proteína e para produzir um aproteína em um aviário
US20110229460A1 (en) 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
BRPI0915948A2 (pt) 2008-07-18 2019-04-09 Talecris Biotherapeutics Inc método de preparar inibidor de alfa-1 proteinase
KR20110084196A (ko) 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
JP5711215B2 (ja) 2009-04-23 2015-04-30 クルセル ホランド ベー ヴェー 組換えヒトアルファ１−アンチトリプシン
ES2332645B1 (es) 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
CN103945862A (zh) 2011-07-07 2014-07-23 Lfb美国股份有限公司 使蛋白质稳定的制剂
US20140296490A1 (en) 2011-08-10 2014-10-02 Laboratoire Français Du Fractionnement Et Des Biotechnologies Highly galactosylated antibodies
CN104302312A (zh) 2011-12-19 2015-01-21 Lfb美国股份有限公司 用于炎性病症治疗的重组人α-1-抗胰蛋白酶
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
US20150175678A1 (en) 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
CA2879763C (en) 2012-08-03 2020-12-01 Simon LOWRY The use of antithrombin in extracorporeal membrane oxygenation
EP2895511A4 (en) 2012-09-10 2016-04-13 Lfb Usa Inc USE OF ANTIBODIES TO TREAT HIV INFECTION AND DELETE HIV TRANSMISSION
US20160002330A1 (en) 2013-02-13 2016-01-07 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Cetuximab with modified glycosylation and uses thereof
AR094781A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos
EP2956480B1 (en) 2013-02-13 2019-09-04 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
FR3005576B1 (fr) 2013-05-15 2015-06-19 Lab Francais Du Fractionnement Procede d'inactivation d'une proteine prion
CN105358228A (zh) 2013-07-05 2016-02-24 法国血液分割暨生化制品实验室 亲和层析基质
FR3015484A1 (fr) 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
WO2015100160A2 (en) 2013-12-24 2015-07-02 Lfb Usa, Inc. Transgenic production of heparin
MX2016015893A (es) 2014-06-02 2017-03-20 Lab Francais Du Fractionnement Produccion de fragmentos de fragmento cristalizable (fc).
FR3022462B1 (fr) 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
US20160158676A1 (en) 2014-12-01 2016-06-09 Laboratoire Français Du Fractionnement Et Des Biotechnologies Method and apparatus for manipulating components of a filtration system

Also Published As

Publication number Publication date
TW201446962A (zh) 2014-12-16
CN105263319A (zh) 2016-01-20
AR094778A1 (es) 2015-08-26
WO2014140927A8 (en) 2015-02-26
US20150374801A1 (en) 2015-12-31
US10034921B2 (en) 2018-07-31
EP2956003A2 (en) 2015-12-23
WO2014140927A2 (en) 2014-09-18
WO2014140927A3 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
BR112015019348A2 (pt) Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
BR112015029904A2 (pt) animais geneticamente estéreis
BR112018010158A2 (pt) roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga
BR112014026186A2 (pt) método de transfecção celular
BR112016011004A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
BR112015019339A2 (pt) Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico
BR112017010793A2 (pt) animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
BR112014018630A2 (pt) alvejamento de glicanos de sulfato de condroitina
BR112013027130A2 (pt) fitase, sequência de ácido nucleico isolada, célula hospedeira recombinante, organismo de produção recombinante, aditivo de alimentação animal, alimentação animal, e, uso de uma fitase
NZ717647A (en) Structure based predictive modeling
BR112016008175A2 (pt) Camundongo geneticamente modificado, e, método para fabricar um camundongo geneticamente modificado
BR112015031155A2 (pt) derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas
BR112016002385A2 (pt) animal não humano, célula, tecido ou embrião, vetor de alvejamento, constructo de vetor de alvejamento, e, métodos para produzir um animal não humano e para modificar um lócus de incrna em uma célula pluripotente
BR112016011003A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
AR095196A1 (es) Medio de cultivo celular libre de suero
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
BR112015019343A2 (pt) Anticorpo anti-her2, composição, método para produção de uma população de anticorpos, células epiteliais das glândulas mamárias, e, mamífero não humano transgênico
MX2016009911A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
BR112019001783A2 (pt) mamífero não humano, e, métodos para produzir o mamífero não humano e de triagem de um composto.
MX2018003354A (es) Seleccion de celulas pluripotentes para producir ratones hembra xy fertiles.
BR112015022801A2 (pt) métodos de produção de pasta de carne melhorada e composições
EA201690831A1 (ru) Способы модулирования размера семян и органов у растений
BR112013033303A2 (pt) métodos para a produção de uma composição cosmética compreendendo leucolectina e usos da mesma
BR112016012014A2 (pt) Barra de sabão
BR112017028619A2 (pt) músculo esquelético humanizado

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2553 DE 10/12/2019.